immunomodulatory drug


Also found in: Acronyms.

immunomodulatory drug

Clinical pharmacology A therapeutic agent that suppresses the immune system, inhibiting lymphocyte functions, especially T and NK cells; IDs are used to treat IBD–ulcerative colitis, Crohn's disease Examples Azathioprine, mercaptopurine Adverse effects BM suppression, pancreatitis; ↑ lymphoma; cyclosporine Adverse effects Renal dysfunction; MTX Adverse effects BM suppression, liver toxicity
References in periodicals archive ?
When immunomodulatory drugs were evaluated for TSEP abnormality no significant difference was determined during the 2-year follow-up (Figure 9).
sup][15],[16] Lenalidomide was a complex immunomodulatory drug, whether other serious adverse effects would be recognized only with long-term use.
About Imprime PGG([R]) Imprime PGGis a novel immunomodulatory drug in development as a cancer therapy.
Idera Pharmaceuticals applies its proprietary Toll-like receptor (TLR) drug discovery platform which has created immunomodulatory drug candidates and has a clinical development program in autoimmune diseases.
s) acquisition of an estimated total of 1,920 units of antineoplastic and immunomodulatory drugs divided into 5 lots.
Fampyra can be used alone or with existing MS therapies, including immunomodulatory drugs.
The Phase 1b trial will investigate the oncolytic virus Reolysin (pelareorep) in combination with immunomodulatory drugs (IMiDs) as a rescue treatment in relapsing myeloma patients.
The ideal therapy for LCH has not yet been established and varies between cytotoxic or immunomodulatory drugs.
Physicians have long debated why patients with lupus are at increased risk for lymphoma, and have repeatedly asked whether immunomodulatory drugs are to blame.
Although metastatic melanoma was previously uniformly lethal, the advent of new therapies including advanced chemotherapeutics and immunomodulatory drugs is substantially improving the prognosis [3].
Topical immunomodulatory drugs and jewelweed are no help
Dr Richard Langley, Director of Research in the Division of Clinical Dermatology & Cutaneous Science at Dalhousie University, presented an overview of the many advanced treatments that have become available only recently, along with an update on the novel small molecule immunomodulatory drugs that are in the pipeline.